| Trial ID: | L4499 |
| Source ID: | NCT00537719
|
| Associated Drug: |
Gsk716155
|
| Title: |
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GSK716155|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change from baseline of the time to 50% gastric emptying (gastric emptying t½) of the solid and liquid components of a meal at 72 hours after dosing in healthy volunteers., 3 Days | Secondary: Exploratory correlation of % contents remaining in stomach after a meal.GSK716155 concentration before meal & at the time gastric emptying is complete. Safety and tolerability parameters each visit., 3 Days
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
34
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-12-07
|
| Completion Date: |
2008-04-04
|
| Results First Posted: |
|
| Last Update Posted: |
2017-08-17
|
| Locations: |
GSK Investigational Site, Lexington, Kentucky, 40503, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00537719
|
